Orchestra Biomed Holdings, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Orchestra BioMed Holdings, Inc. reported a net loss of $52.7 million for 2025, while advancing key clinical trials for its AVIM Therapy and Virtue SAB product candidates and securing new financing.
NASDAQ
Orchestra BioMed Holdings details its 2024 financial performance, highlighting progress in clinical trials and strategic partnerships amid ongoing financial challenges.
NASDAQ
Orchestra BioMed's 10-K filing details its authorized and outstanding stock, warrants, registration rights, and corporate governance, providing a comprehensive overview of its securities structure.